01.02.2011 • NewsAcronRussiaSilvinit

Acron to Challenge Silvinit and Uralkali Merger In Court

Russian fertilizer producer Acron will challenge the merger between potash companies Silvinit and Uralkali in court, as it ups its opposition to the deal.

A spokesperson for Acron, which owns 8% of Silvinit, said it had lodged a claim at a court in Perm, east of Moscow, ahead of a Feb. 4 vote on the deal by shareholders.

Uralkali said it would fight the claims, saying they were "without merit." The Acron spokesperson declined to elaborate on the detail of the claims.

A merger of Silvinit and Uralkali to create a Russian potash mining giant was engineered by billionaire tycoon Suleiman Kerimov, who bought controlling stakes in both companies alongside associates last summer.

Potash, a key ingredient in fertilizer, has emerged as a valuable commodity in a world struggling to feed a growing population while battling droughts and floods.

Moscow's Investor Protection Association said late last year Silvinit shareholders should vote against the deal as it strongly favored investors in Uralkali.

Acron voted against the deal at a board of directors meeting last year.

Kerimov, who serves in Russia's upper house of parliament, will be left with 16% of the combined group after the deal is completed.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.